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Background: Cytogenetic analysis has detected an accumulation of genetic lesions in oral cancers. Numerical changes
in chromosome 17 might be associated with an up-regulation of p53 gene, and could contribute to critical events in
carcinogenesis. The aim of this study was to reveal possible correlations between the numerical aberrations of
chromosome 17, deletion or amplification of the P53 gene and histological grading in patients with oral
squamous cell carcinoma (OSCC).
Methods: This study was performed retrospectively on anonymous forty paraffin embedded specimens diagnosed
with a primary OSCC. Sections were prepared for p53 immunohistochemical staining and FISH technique
evaluation.
Results: All studied cases showed a positive nuclear staining with different indices for the p53 protein.
Furthermore, statistical analysis showed a significant difference between all histological types of OSCC. In term of
P53 immunoreactivity well differentiated OSCC showed the highest, whereas poorly differentiated showed
weakest. Regarding chromosome 17 aberrations and p53 gene mutations, Spearman correlation test revealed a
statistical significant positive correlation between chromosome 17 abnormalities and p53 gene mutations as well
as with the immunohistochemical expression of p53 proteins. Moreover, the positive association between p53
gene mutations and the expression of p53 protein was statistically significant.
Conclusion: In the light of the previous findings, we concluded that numerical aberrations of chromosome 17 and
p53 gene mutations as well as expression of p53 protein have enormous influence on various cellular processes
including differentiation and carcinogenesis. Such knowledge provides an easy and simplified approach to
prognosis predilection for OSCC.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2015_232.
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The development of oral squamous cell carcinoma
(OSCC) depends on both environmental and genetic
factors. Most oral cancer cases have had prolonged ex-
posure to tobacco and alcohol, but these carcinogens
cannot fully account for the development of cancers in
these individuals [1]. Numerous studies have shown that* Correspondence: zedanwalid@hotmail.com
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unless otherwise stated.tobacco causes damage of the cell DNA and alcohol re-
duces the effectiveness of DNA repairing that would be
needed [2]. The accumulations of genetic abnormalities
in carcinogenesis are divided into four phases: initiation,
promotion, conversion and progression [3]. Cytogenetic
analysis has detected an accumulation of genetic lesions in
oral cancers [4]. Numerical changes in chromosomes 7 and
17 might be associated with an up-regulation of p53 gene,
and could contribute to critical events in laryngeal carcino-
genesis [4]. Moreover, human papillomavirus-associated
oropharyngeal carcinoma (HPV-associated oropharyngealThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathological variables of studied cases
Patients characteristics Number (%)
Age ≤40 years 8 20%
>40 years 32 80%
Sex Male 28 70%
Female 12 30%






Stage I 4 10%
Stage II 8 20%
Stage III 16 40%
Stage IV 12 30%







Poorly differentiated 8 20%
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and unregulated expression of oncogenes and tumor sup-
pressor genes might be involved in the pathogenesis of
OSCC [6]. Molec-specific DNA probes, facilitate the con-
firmation of presumed chromosomal aberrations with
high sensitivity and specificity. The acquisition of genetic
instability is an essential step during carcinogenesis [7]. In
most tumors, including OSCC, such a genomic changes
result in alteration of chromosomal number and structure.
A high frequency of chromosome 17 abnormalities has
been reported in some human cancers such as breast car-
cinoma, colon carcinoma and bladder carcinoma [8-10].
Different studies revealed that cells with polysomy of
chromosome 17 are significantly increased in squamous
cell carcinoma the previous finding might indicate that
chromosome 17 abnormalities seems to be correlated with
carcinogenesis of OSCC [11].
The development and progression of human tumors
often involves inactivation of tumor suppressor gene
function [12]. The P53 gene, located on the short arm of
chromosome 17p13, consists of 11 exons coding for a
nuclear phosphorprotein, which can bind to specific
DNA sequences acting as a transcription factor. Dys-
function in the P53 tumor suppressor gene is involved in
the etiopathogenicity of OSCC [4]. The exact role of the
p53 genetic alterations in different stages of the tumori-
genic process is not completely established. The p53
gene has the capacity to induce repair of the damaged
DNA by activating repair proteins and by stopping the
cell cycle at the G/S regulation point, arresting growth
of the cells. Another anti-cancer role of P53 is initiating
apoptosis of a cell with irreparable DNA damage [13].
The aim of this study was to identify numerical aberra-
tions of chromosome 17, deletion or amplification of
P53 gene and to reveal possible correlations between
these abnormalities and histological grading in patients
with OSCC to be used as an easy and simplified prog-
nostic marker.
Methods
This study were performed retrospectively on forty an-
onymous paraffin embedded blocks diagnosed with a pri-
mary OSCC and clinical data were obtained without any
personal information’s on those cases from the archives of
faculty of Dentistry, Oral Pathology Department and the
Oncology center of Mansoura University, Egypt between
the years 2010 and 2013. Tumor samples were processed
by usual techniques for inclusion in paraffin in the path-
ology lab of faculty of Medicine, Mansoura University. 3
micrometer-thick sections from the paraffin blocks were
stained with hematoxylin-eosin for the establishment of
the histopathological type and differentiation stage, based
on the WHO International Classification of Diseases for
Oncology (1990). Clinical staging was performed usingthe TNM Staging. Additional sections were prepared for
immunohistochemical analysis and FISH technique evalu-
ation. Five normal control slides obtained from mucosal
specimens of non-oral cancer patients for this compara-
tive study. Details of the cases are given in Table 1.
p53 immunohistochemistry
The sections were deparaffinized in xylene and rehydrated
in alcohol. Endogenous peroxidase activity was quenched
by immersion in a 1:4 solution of 3% hydrogen peroxide
in methanol for 20 min, followed by rinsing several times
in Tris-buffered saline (TBS). Slides were placed in Copin
jars containing a 1:10 solution of target retrieval solution
(Target Retrieval Solution 10×, pH9.0, Dako Cytomation
S2367, Glostrup, Denmark) in distilled water and heated
in a water bath at 98°C for 20 min to unmask the antigen.
After the heating steps, the jars were allowed to cool for
30 min. Nonspecific binding was blocked by incubation
with 5% bovine serum albumin (BSA) in TBS for 30 min
at room temperature, the slides were incubated with the
primary anti-P53 at a dilution of 1:200 in antibody diluent
(Antibody diluent, Dako Cytomation) overnight at room
temperature in a moist chamber. The slides were rinsed in
TBS (3 times for 10 min each) and then incubated with
secondary antibody (EnVision detection Kit Peroxidase/
DAB Rabbit/mouse, Dako Cytomation) according to the
manufacturer’s instructions. The slides were rinsed in TBS
(3 times for 10 min each) and then stained with 3,3′-
diaminobenzidinetetrahydrochloride (EnVision detection
Kit Peroxidase/DAB Rabbit/mouse, Dako Cytomation).
Zedan et al. Diagnostic Pathology  (2015) 10:2 Page 3 of 9Sections were counterstained with Mayer’s haematoxylin
solution. Negative controls were run in parallel, replacing
the primary antibody with antibody diluent. The immuno-
reactive protein was localized in cancer cell nuclei.
Digital image analysis
Slides were photographed using Olympus® digital camera
installed on Olympus® microscope with 1/2 X photo
adaptor, using 40 X objective. The images were analyzed
on Intel® Core I3® based computer using VideoTest
Morphology® software (Russia) with a specific built-in
automated object counting routine for immunohistostain
analysis. The immunoreactivity in the malignant cells
in each section was graded according to the number of
positively staining nuclei: ≤ 1% nuclei with a positive
reaction are considered as a negative, > 1 ≤ 10% as low
(+), >10% ≤ 50% as intermediate (++) and > 50% as high
(+++).
Interphase FISH analysis
Interphase FISH technique was done on thin
formalin- fixed paraffin- embedded material. Using the
Olympus BX 61, fluorescent microscope equipped with
appropriate filters suitable for Fluorescein, Rhodamine
and DAPI which present in Oncology Center, Faculty
of Medicine, Mansoura University. Representative im-
ages were captured via a monochrome digital camera
using Cytovision Image Capture software (Applied
Imaging).
Technique
Interphase FISH technique was performed on tissue sec-
tions after optimization of the protocol using commer-
cially available probe from Vysis, locus specific identifier
LSA TP53/CEP 17 FISH Probe Kit which is intended to
detect the copy number of the LSI TP53 probe Spectrum
Orange target located at chromosome 17p13.1 and of the






















Figure 1 Shows the mean ± SD of P53 immunohistochemical expressiGreen Dual Colour target located at the centromere of
chromosome 17 according manufacturer’s protocol
Abbott/Vysis (Vysis, Downers Grove, IL, USA). Sec-
tions were deparaffinized in xylene (3 times each for
5 min) and dehydrated in ethanol (3 times each for
3 min). Sections were pre-treated by placing the slides
in 1xHCL (hydrochloric acid) 0.1 M for 20 minutes to
avoid tissue autofluorescence, then the slides were
placed in 2X SSC (Standard Saline Citrate) wash in a
coplin jar for 3 minutes. The slides were then heated in
microwave at 99°C in 1 mM sodium citrate buffer
(pH 6.0) for 60 min, followed by 3 min in distilled
water, 20 min in pepsin solution (Sigma P8038)
(0.05 mg/mL pepsin solution in N HCL 0.01 M) at 37°C
followed by washing in distilled water for 3 min and dehy-
drating for 1 min in increasing concentrations of alcohol
(70, 85 and 100%) after which they were air-dried. Then
20 ul of 50% formamide hybridization buffer was added to
the marked area on the slide and incubated at 90°C for
20 min on the HyBrite™ machine (Olympus Life Science).
After that five μl of probe solution were applied to each
slide, overlaid with a coverslip, which was sealed with rub-
ber cement. Slides were denatured for 5 min at 73°C and
hybridized for at least 16 h at 37°C in a Vysis HyBrite™
machine. Following hybridization, the slides were
washed with 2 × SSC/0.1% NP40 at room temperature
for 5 min then at 73°C with 0.4 × SSC/0.3% NP40 for
2 min and again at room temperature with 2 × SSC/
0.1% NP40 for 1 min. After air-drying in the dark,
slides were counterstained with 10 μl of 4′6′-diamino-
2-phenylindole (DAPI II). A cover slip was applied and
sealed with nail varnish. The slides were analyzed
Using the Olympus BX 61, fluorescent microscope
(Olympus Life Science) equipped with appropriate fil-
ters suitable for Fluorescein, Rhodamine and DAPI.
Representative images were captured via a mono-
chrome digital camera using Cytovision Image Capture







NK mod. Diff. scc.
Poorly diff. scc.
on in different histological grades of the studied SCC cases.
Figure 2 Well differentiated SCC revealed intense
immunoreactivity for p53.
Figure 4 Keratinizing moderately differentiated SCC revealed a
moderate p53 immunopositivity.
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The LSI P53 probe hybridizes to chromosome 17. The
approximately 172 kb Spectrum Orange P53 probe con-
tains the complete TP53 gene and is located at chromo-
some 17p13.1. The Spectrum Green CEP 17 probe is a
control probe which hybridizes to the centromere region
of chromosome 17p11.1-q11.1. All the patients’ subjects
presented the numerical alterations in the chromosome
17 and the P53 gene. On hundred nuclei were scored
under x100 magnification, using an oil immersion ob-
jective and the fluorescent microscope for each definedFigure 3 Poorly differentiated SCC showed mild p53
immunoreactivity.histological area from the tumor and tumor-adjacent
epithelia, each nucleus being assessed for the chromo-
some copy number. The numerical aberrations of
chromosome 17 varied from individual to individual.
Specifically, only distinct isolated nuclei were counted.
We interpreted as monosomy 17 if the mean number of
green signals in analyzed cells for each subject was lower
than two. Chromosome polysomy was defined as the
fraction of the cells demonstrating three or more green
signals in each nucleus. In normal cell, therefore there
should be 2O2G signals. We interpreted as P53 gene de-
letion if the there is one orange signal in analyzed cells
for each subject. Multiplication in P53 gene was defined
as demonstrating more than 2 orange signals in eachFigure 5 Non- keratinizing moderately differentiated SCC
showed moderate p53 immunoreactivity.
Table 2 Shows the mean ± SD of P53 immunohistochemical expression in different histological grades of the studied
SCC cases (ANOVA)




Poorly diff. SCC ANOVA P value
Mean ± SD 74.40 ± 3.22 60.00 ± 4.07 32.00 ± 1.15 7.00 ± 1.69 0.000
P1 0.000 0.000 0.000
P2 0.000 0.000
P3 0.000
All results are expressed as mean ± SD.
Non significant: at P >0.05.
Significant: at P < 0.05.
P1 = significance between Well differentiated SCC group and other groups.
P2 = significance between Keratinizing moderately differentiated SCC and other groups.
P3 = significance between Non Keratinizing moderately differentiated SCC and Poorly differentiated SCC.
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used.
Statistical analysis
Statistical analysis of the data was done by using Statis-
tical Package for Social Science (SPSS) version 20.0
Qualitative variables were presented as number and per-
cent. Quantitative variable were presented as mean ± SD.
Kendall’s tau-b correlation was used to assess relations
between variables. Significance was considered when P
value < 0.05.
Results
This study included forty cases of OSCC with a high
tendency for occurrence in old male patients (all of the
males were smokers). Most of the cases were outdoor
workers (farmers & street venders). All the tumors were
intraoral and the tongue was the most common site
(40%). In relation to the TNM staging system, majority
of cases were stage III and stage IV respectively (40%,
30%). Among the histological grades, well differentiated
type was the most frequent (50% of all studied cases)
(Table 1).
Immunohistochemically, all studied cases showed a
positive nuclear staining for the p53 protein with different
indices (Figure 1). Well differentiated form of SCC
showed the highest extent of P53 immunoreactivity
(mean ± standard deviation (SD) = 74.40 ± 3.22) (Figure 2),
whereas poorly differentiated cases showed lowest immu-
nopositivity for p53 (mean ± SD = 7.00 ± 1.69) (Figure 3).Table 3 The mean number of signals for chromosome 17 abno
grades of the studied SCC cases
Grade Number
(total = 20)
Well differentiated SCC 20
Keratinizing moderately differentiated SCC 8
Non-keratinizing moderately differentiated SCC 4
Poorly differentiated SCC 8In moderately differentiated SCC cases, the tumor
staining for p53 was intermediate but with different ex-
tents in keratinizing and none keratinizing subtypes.
The keratinizing moderately differentiated variant re-
vealed a higher level of p53 immunoreactivity (mean ±
SD = 60.00 ± 4.07) (Figure 4) than the non- keratinizing
subtype (mean ± SD = 32.00 ± 1.15)(Figure 5). Statis-
tical analysis of these findings showed a significant dif-
ference between all histological types of OSCC in
relation to the immunohistochemical expression of
p53 protein (Table 2).
In the present study as shown in Tables 3 and 4; 28
subjects (70%) with chromosome 17 trisomy and only 8
subjects (20%) with chromosome 17 monosomy (Figures 6
and 7) were detected. Cases with chromosome 17 trisomy
presented p53 gene amplification or multiplication while
the cases with chromosome 17 monosomy revealed p53
gene deletion (Figures 6 and 7). All well differentiated
SCC cases as well as the keratinizing moderately differen-
tiated SCC type showed chromosome 17 and p53 gene
amplification or duplication. On the opposite side, all
poorly differentiated SCC cases exhibited chromosome 17
and p53 gene deletion (Figure 6). The non-keratinizing
moderately differentiated variant presented a striking find-
ing. They revealed p53 gene deletion while the chromo-
some 17 was normal (Figures 6 and 8).
The Spearman correlation test revealed a statistical
significant positive correlation between chromosome 17
abnormalities and p53 gene mutations as well as with
the immunohistochemical expression of p53 proteinsrmalities and p53 gene mutations in different histological
Mean number of signals





Table 4 Shows chromosome 17 abnormalities, P53 gene mutations in different histological types of the studied SCC
cases
Comparison Well differentiated
SCC (No & %)
Keratinizing moderately
differentiated SCC (No & %)
Non keratinizing moderately
differentiated SCC (No & %)
Poorly differentiated
SCC (No & %)
Multiplication Chromosome 17 20 (100%) 8 (100%) 0 0
P53 gene 20 (100%) 8 (100%) 0 0
Normal Chromosome 17 0 0 4 (100%) 0
P53 gene 0 0 0 0
Deletion Chromosome 17 0 0 8 (100%)
P53 gene 0 0 4 (100%) 8 (100%)
Total number 20 8 4 8
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p53 gene mutations and the expression of p53 protein
was statistically significant (P = .000) (Table 5).
Discussion
Universally, it is accepted now that alterations in mul-
tiple oncogenes and tumor suppressor genes are the
genetic basis for human carcinogenesis [12]. The p53
gene is the most frequent target of genetic alterations,
being mutated in half of human cancers [13]. The p53
mutation usually shows clonality in cancer, therefore it
has occurred in the early stage of carcinogenesis, as in
OSCC [14]. A very recent research used low copy num-
ber of mitochondrial DNA (mtDNA) to predict worse
prognosis in early-stage laryngeal cancer patients [15].
So far, prognosis prediction will be the focus of cancer
researchers for the assurance of saving cancer patients
lives.
In the present study, (40%) of the OSCC cases were
found in the tongue. This is the same as compared to
most of the other studies [16,17]. Moreover, it was foundFigure 6 FISH analysis using LSI P53 Spectrum Orange/CEP 17
Spectrum Green Probe. One signal for each fluorochrome showing
monosomy 17 and p53 deletion.that (80%) of the cases were in the 40 year or above age
group (n = 32). Overall male: female ratio of about 2.33:
1. This is in accordance with other studies, as reported
by Idris et al. and Sugarman et al. [18,19].
According to Llewellyn et al. [20], SCC is not so fre-
quent in young patients. Only 1% to 6% of SCC cases
occur in patients under the age of forty indicating that
the occurrence in children and adolescent was extremely
rare [20,21]. Surprisingly, in our study, patients under
40 years of age were reported as 20% (n = 8). This shows
that the incidence of oral cancer among young patients
has markedly increased in our country. From our results
most of the patients were exposed to sun light and male
patients were smokers the previous information’s are inFigure 7 FISH analysis using Vysis LSI TP53 Spectrum Orange/CEP
17 Spectrum Green Probe. Three specific green signals fo trisomy 17











Figure 8 Shows chromosome 17 abnormalities, P53 gene
mutations in different histological types of the studied
SCC cases.
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tors [20]. Finally, these results may be also due to the in-
crease of nutritional deficiencies, pesticides pollution
and drugs addictions in youngster.
Regarding TNM staging of SCC, most of patients pre-
sented in stage III (40%) and stage IV (30%), respectively.
This is almost the same as described by HAQ M et al.
[17]. This indicates that SCC in our country is detected
or diagnosed mostly in advanced stages which were in
contrast to Manuel et al. and Okada et al. who showed
presentation of the cases at their early stages [22,23].
This might be due to the fact of high illiteracy rate, ig-
norance about the disease and poor referral system in
our country. In addition, Shah et al., 2010 reported that
oral cancers are diagnosed late (Stage III and IV) in
Pakistan and need immediate public and professional at-
tention [24].
Well differentiated was the most common histopatho-
logical type of OSCC in our study. This finding is in
contrast to Haq M et al., whom found that poorly differ-
entiated SCC was the most prevalent histological variant
[17]. In accordance with the findings of our study,
Valerie et al. reported that poorly differentiated subtype
of SCC occurs much less commonly than well differenti-
ated variant [25,26].Table 5 Shows the Spearman correlations between chromoso
immunohistochemical expression of P53 protein in different
Comparison Chromosome
abnormalitie
chromosome 17 abnormalities r 1.000
P value
P53 gene mutations r .988
P value .000
Significant : at P < 0.05.In the present study, it was found that a positive nu-
clear staining for the p53 protein with different indices
in all studied cases. This finding is in agreement with
Bai L, Zhu W-G 2006, whom suggested that p53gene is
known to play a key role in all types of human cancers
[27]. This could be attributed to the significant involve-
ment of p53 gene in oncogenesis as p53 gene plays a
pivotal role in regulation of the cell cycle and induction
of apoptosis. In addition, it were noticed that the charac-
teristic feature of the p53 gene mutational map is the
high frequency of missense point mutations. Unlike
many other tumor suppressor genes, more than 80% of
p53 gene mutations result in single amino-acid substitu-
tions which lead to the synthesis of a stable full-length
protein rather than deletions. These missense mutations
lead to the synthesis of a protein that lacks specific DNA
binding site and accumulates in the nucleus of tumor
cells [28]. Furthermore, it was found that p53 gene to be
overexpressed in 63% of oral carcinomas [3]. From the
previous finding we can hypothesize that accumulation
of the P53 protein in an inactive form might has a role
in the development of OSCC. There is now strong evi-
dence that mutation not only abrogates p53 tumor-
suppressive functions, but in some instances can also
endow the mutant proteins with novel activities. Such
neomorphic p53 proteins are capable of dramatically al-
tering tumor cell behavior, primarily through their inter-
actions with other cellular proteins and regulation of
cancer cell transcriptional programs [29].
An interesting observation was noted in the present
study that highly differentiated tumors had a high p53
immunostaining whilst poorly differentiated showed a
significantly weaker immunohistochemical expression
of p53 compared with well differentiated form. These
results are consistent with other studies which have
demonstrated that; statistically significant co-relation
was seen between the histological grade and p53 gene
overexpression. Also, histological parameters which in-
dicated high cellular turnover were also significantly
associated with p53 gene overexpression [30]. This
might be interpreted as most of the mutations in the
poorly OSSC is truncating mutations (deletions) which
may lead to less P53 protein production and absence of
its reactivity in the nucleus which in turn indicatingme 17 abnormalities, P53 gene mutations and
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[31-33].
In our study, a statistical significant positive correl-
ation was found between chromosome 17 abnormalities
and p53 gene mutations. Cases with chromosome 17 tri-
somy presented p53 gene amplification or multiplication
while the cases with chromosome 17 monosomy re-
vealed p53 gene deletion. Furthermore, keratinizing SCC
cases exhibited amplification of chromosome 17 and p53
gene while poorly differentiated exhibited chromosome
17 and p53 gene deletions. Interestingly, mutations in
the p53 gene occur at different phases of the multistep
process of malignant transformation [34]. In accordance,
Kozomara et al. mentioned that p53 deletions are associ-
ated with a higher risk of relapse and contribute to an
even worse prognosis of patients with OSCC [35]. More-
over, numerical changes in chromosomes 17 might be
associated with an up-regulation of p53 genes, and could
contribute to critical events in laryngeal carcinogenesis
[4]. Other data from literature revealed that the fre-
quency of cells with polysomy increased with histological
progression suggesting that the biological factors might
influence the rate of accumulation of genetic hits. Gen-
omic instability may also lead to chromosome non-
disjunction and to the generation of cells with zero,
one, two, and three or more chromosome copies [36].
Also, altered p53 gene expression in premalignant le-
sions is associated with increased chromosomal polys-
omy [3]. Hence, the presence of cells exhibiting three
or more chromosome copies (chromosome polysomy)
might be considered a quantitative marker of ongoing
or accumulated genomic instability in tumors [37,38].
This study revealed a statistical significant positive cor-
relation between chromosome 17 abnormalities and the
immunohistochemical expression of p53 proteins. Other
previously reported findings suggest that a statistically
significant correlation existed between p53 protein ex-
pression and polysomy 17 [36,39,40]. Furthermore, p53
protein overexpression was associated with the fre-
quency of p53 mutations in tumor tissue, while p53 mu-
tations, particularly missense and nonsense mutations
might have some impact on survival rate [39]. This
could be explained by Fritsche et al. who indicated that
wild type p53 activation involves an increase in overall
p53 protein level as well as qualitative changes in the
protein through extensive post-translational modifica-
tion, thus resulting in activation of p53-targeted genes
[41]. Moreover, the immunohistochemically detectable
high p53 gene expression levels reflect the increased
half-life of the protein encoded by a mutated gene
[42,43]. Also, Busby-Earle et al. concluded that somatic
mutation in the hotspot regions of the p53 gene occurs
infrequently in cervical carcinomas; that immunocyto-
chemically detectable levels of p53 are also infrequent[44]. Upon these results, it is assumed that polysomy in
chromosome 17 correlates with the mutation of p53
gene which results in an accumulation of aberrant p53
protein.
Conclusion
In the light of the current study findings, we found that
numerical aberrations of chromosome 17, p53 gene mu-
tations as well as expression of p53 protein have massive
influence on various cellular processes including differ-
entiation and carcinogenesis as mutant p53 can induce
an increased epigenetic instability of tumor cells, facili-
tating and accelerating the evolution of the tumor. From
our results, we conclude that bad prognosis (aggressive
tumors) is directly correlated with chromosome 17 aber-
rations and P53 deletion mutation. Finally, such know-
ledge provides an easy and simplified approach to
prognosis predilection for OSCC.
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